{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2"}]}],"title":"Pre-Rituximab (N=490)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1"}]}],"title":"Post-Rituximab (N=491)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"491"}],"units":"Participants"}],"description":"A low immunoglobulin concentration was defined as a concentration below the lower level of normal.","groups":[{"description":"Participants received 0.5 g or 1.0 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.\n\nParticipants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.\n\nAll participants entered a 48-week safety follow-up (SFU) period following the treatment period.","id":"OG000","title":"Rituximab + MTX"}],"paramType":"NUMBER","populationDescription":"Safety follow-up population: All participants who were randomized and received any part of a rituximab infusion. Number of participants analyzed = participants with available data. \"N\" indicates the number of participants with non-missing data at each time point.","reportingStatus":"POSTED","timeFrame":"Baseline (pre-rituximab), Beginning of the safety follow-up period to the end of the study (approximately 6 years) (post-rituximab)","title":"Percentage of Participants With Low Immunoglobulin Concentrations Pre- and Post-Rituximab Treatment","type":"POST_HOC","unitOfMeasure":"Percentage of participants"}